TL;DR
This study simulates the impact of different lipid-lowering therapies (LLTs) on achieving optimal LDL-C goals in China, revealing that moderate-intensity statins are highly effective for most, but a significant portion of high-risk individuals require additional, more potent treatments. The findings highlight an opportunity to reduce the substantial burden of atherosclerotic cardiovascular disease (ASCVD) in China by optimizing LLT strategies and improving access to these medications.
What Problem Does This Paper Address?
Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death in China, with high levels of low-density lipoprotein cholesterol (LDL-C) being a significant contributor. While guidelines recommend lipid-lowering therapies (LLTs) to manage LDL-C and reduce ASCVD risk, there's a knowledge gap regarding the specific proportion of the Chinese population that needs various LLT regimens to reach optimal LDL-C targets. Understanding this "LLT requirement" is crucial for developing effective public health strategies, allocating healthcare resources efficiently, and ultimately curbing the rising ASCVD burden in China.
Methods
The researchers employed a simulation study using data from the China PEACE MPP (Patient-Centered Evaluative Assessment of Cardiac Events Million Persons Project) cohort, which included over 2.9 million participants aged 35-75 from across mainland China. They utilized a Monte Carlo simulation model, a technique that estimates outcomes through repeated random sampling, to model stepwise LLT intensification. This involved simulating scenarios where participants, stratified by their 10-year ASCVD risk, would receive progressively stronger LLTs (starting with moderate-intensity statins, then adding ezetimibe, and finally a PCSK9 inhibitor like evolocumab) until their LDL-C goals were met. The model assumed participants had already adopted lifestyle modifications and adhered to treatments.
Datasets
The primary dataset used was the China PEACE MPP population cohort, a nationwide screening project that collected data from 2,904,914 participants between 2015 and 2020. This dataset provided information on demographics, lifestyle, medical history, and lipid measurements. For cost estimations, data on medication prices were sourced from national centralized medicine procurement policies and local government procurement catalogs. Age and sex standardization was performed using the 2010 population census of China.
Key Insights and Ideas
- Statin Powerhouse: Moderate-intensity statins are remarkably effective, capable of bringing over 99% of individuals in low and moderate ASCVD risk categories to their LDL-C goals. This underscores their foundational role in ASCVD prevention.
- The High-Risk Gap: A substantial percentage of individuals in high (11.3%) and very-high (24.5%) ASCVD risk categories still fail to reach their LDL-C targets even after simulated atorvastatin therapy, highlighting the need for more aggressive treatment strategies in these groups.
- Tiered Therapy is Key: The simulation demonstrates a clear escalation of treatment needs. After statins, ezetimibe is required for a subset of high-risk patients, and a further group necessitates PCSK9 inhibitors. This tiered approach is essential for personalized risk management.
- Cost-Effectiveness of Statins: The study reinforces that statins are the most cost-effective intervention, with a significantly lower cost per prevented event compared to ezetimibe and evolocumab.
- China's Unique Landscape: While China has a lower proportion of high-risk individuals compared to Western countries, the age-standardized incidence and mortality of cardiovascular events are higher, suggesting a potential for greater ASCVD risk per LDL-C level in the Chinese population. This implies that optimizing LLT could yield substantial public health benefits.
Key Results
- After standardizing for age and sex, the study population was stratified into low (70.8%), moderate (15.6%), high (11.5%), and very-high (2.1%) ASCVD risk groups.
- Following simulated atorvastatin 20 mg therapy, over 99% of low and moderate-risk individuals achieved their LDL-C goals.
- However, 11.3% of high-risk and 24.5% of very-high-risk individuals still required additional non-statin therapy.
- After adding ezetimibe, 4.8% of high-risk and 11.3% of very-high-risk individuals still needed evolocumab.
- With the full LLT intensification (statin, ezetimibe, evolocumab), over 99% of all participants achieved their LDL-C goals.
- The annual costs for LLT intensification were estimated at $2.4 billion for statins, $4.2 billion for statin + ezetimibe, and $24.5 billion for statin + ezetimibe + evolocumab.
- These interventions were projected to prevent 264,170 cardiovascular events with statins alone, 18,390 with statin + ezetimibe, and 17,045 with the full regimen.
Limitations and Future Work
The authors acknowledge several limitations:
- Convenience Sampling: The study used a convenience sampling design, though demographic profiles were consistent with national census data, and age/sex standardization was applied.
- LDL-C Calculation: LDL-C was calculated using the Friedewald equation, which can underestimate levels in individuals with high triglycerides.
- Generalizability of Treatment Effects: Treatment effects were based on clinical trials with limited Chinese participants, although prior studies suggest similar pharmacokinetics between Western and Asian populations for atorvastatin.
- Lifestyle Modification Assumption: The simulation assumed sufficient lifestyle modifications, which may not reflect real-world adherence in China.
- Simplification of Scenarios: The model did not account for nonadherence or statin intolerance, which could slightly increase the proportion requiring non-statin therapy.
Future work could explore the cost-effectiveness of emerging lipid-lowering agents, investigate the role of other lipid markers (like apolipoprotein B and Lp(a)) in risk stratification, and assess the impact of nutraceuticals and newer medications (e.g., bempedoic acid, evinacumab, inclisiran) in managing dyslipidemia and ASCVD. Further research is also needed to determine if lower LDL-C thresholds for initiating LLT and achieving goals are appropriate for the Chinese population.
Summary updated